tiptop published ATDS 2026 to explain our requirements for product evidence in full. Material identity, actual delivery and human outcomes need to connect around the same product. We set out this approach in an enterprise technical white paper as a shared basis for research and development, quality management and public communication.
From raw-material information to the finished product
A material may have a research foundation, yet entering a formulation raises new questions: how it is stored in packaging, how it is released during use, where it reaches and what effects are observed. We need a continuous evaluation framework that includes these stages in the same development process.
ATDS stands for Advanced Transdermal Delivery Standards for Consumer Anti-aging. The current public edition is the August 2026 Enterprise Initiative Edition Version 1.0. Its English original runs to 42 pages, with 17 chapters, a conclusion, Appendices A–E and 40 references.
This is an enterprise technical initiative proposed by tiptop. By publishing it, we also invite professional discussion of its methods and judgments.
Three evidence chains organize our work
The identity chain records what a material is, where it comes from, its composition, quality attributes and batch history. Subsequent evaluation must begin with a clearly defined subject.
The delivery chain starts with the final formulation and examines ingredient release under actual conditions of use, together with distribution in the intended skin or follicular locations.
The outcome chain connects safety, tolerability and human performance with public product statements. Every result must correspond to a product version, method of use and evaluation conditions.
These three chains structure our product evidence. They extend development from materials through actual use and provide a traceable basis for later version changes.
This edition focuses on topical use on intact skin
ATDS 2026 covers conformity for topical products used on intact skin and non-invasive scalp products. Transmucosal routes, including oral and sublingual routes, appear as research extensions. Microneedling, injections, damaged skin and systemic delivery fall outside this edition’s conformity scope.
The full text is available on the ATDS 2026 public page. Its main sections are organized as follows.
| Content | Chapters |
|---|---|
| Scope and terminology | 1–2 |
| Evaluation pathway and nine evidence gates | 5–7 |
| Identity of EVs and human-derived materials | 8 |
| Facial care, scalp care and quality work | 9–11 |
| Transmucosal-delivery research extensions | 12 |
| Enterprise evaluation and public statements | 13–15 |
| Governance and future updates | 16–17 and appendices |
Alongside the framework, we will present evaluations for individual products, explaining both the requirements we set and the work actually completed for each product.